Aubagio for MS in Oz
November 22, 2012
THE Therapeutic Goods
Administration has approved
Aubagio (teriflunomide) 14mg, for
the treatment option for people
with multiple sclerosis (MS).
The drug is indicated for patients
with relapsing forms of MS to
reduce the frequency of clinical
relapses and to delay the
progression of physical disability.
Aubagio is an immunomodulator
with anti-inflammatory properties.
According to Genzyme, Aubagio
shows statistically significant
efficacy across key measures of MS
disease activity, including reducing
relapses, slowing the progression of
disability and improvement in a
number of MRI measures.
The drug has shown significant
reductions in both annualised
relapse rate and disability
progression in two large, phase III,
placebo-controlled clinical trials.
Aubagio is not currently PBS
listed, however it is available to
appropriate patients with MS
through a Product Familiarisation
Program, conducted in
collaboration with Australian
neurologists.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Nov 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Nov 12
